- Home
- SLRX vs SCNI Comparison
SLRX vs SCNI Comparison
Compare SLRX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- SCNI
- Stock Information
- Founded
- SLRX N/A
- SCNI 2003
- Country
- SLRX United States
- SCNI Israel
- Employees
- SLRX N/A
- SCNI N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLRX Health Care
- SCNI Health Care
- Exchange
- SLRX Nasdaq
- SCNI Nasdaq
- Market Cap
- SLRX 2.1M
- SCNI 2.0M
- IPO Year
- SLRX N/A
- SCNI N/A
- Fundamental
- Price
- SLRX $0.50
- SCNI $1.52
- Analyst Decision
- SLRX
- SCNI
- Analyst Count
- SLRX 0
- SCNI 0
- Target Price
- SLRX N/A
- SCNI N/A
- AVG Volume (30 Days)
- SLRX 6.2M
- SCNI 3.0M
- Earning Date
- SLRX 08-19-2025
- SCNI 08-19-2025
- Dividend Yield
- SLRX N/A
- SCNI N/A
- EPS Growth
- SLRX N/A
- SCNI N/A
- EPS
- SLRX N/A
- SCNI N/A
- Revenue
- SLRX N/A
- SCNI $658,000.00
- Revenue This Year
- SLRX N/A
- SCNI N/A
- Revenue Next Year
- SLRX N/A
- SCNI N/A
- P/E Ratio
- SLRX N/A
- SCNI N/A
- Revenue Growth
- SLRX N/A
- SCNI N/A
- 52 Week Low
- SLRX $0.45
- SCNI $1.40
- 52 Week High
- SLRX $7.20
- SCNI $6.18
- Technical
- Relative Strength Index (RSI)
- SLRX 37.62
- SCNI 29.96
- Support Level
- SLRX $0.59
- SCNI $1.40
- Resistance Level
- SLRX $2.31
- SCNI $1.64
- Average True Range (ATR)
- SLRX 0.18
- SCNI 0.24
- MACD
- SLRX -0.02
- SCNI -0.03
- Stochastic Oscillator
- SLRX 2.27
- SCNI 5.77
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.